Table 4.
Scores for primary efficacy outcome measures
| Sleep treatment at acute crisis (n = 20) | Standard care (n = 20) | Adjusted mean difference between groups (95% CI) | Between-group standardised effect size (d) | |
|---|---|---|---|---|
| Primary efficacy outcome measures | ||||
| Insomnia (ISI) | ||||
| Week 0 | 17.1 (6.0) | 16.1 (4.9) | ||
| Week 2 | 8.5 (5.4) | 12.5 (5.5) | −4.6 (−7.7 to −1.4) | −0.9 |
| Week 4 | 6.8 (5.2) | 10.1 (5.6) | −3.6 (−7.0 to −0.3) | −0.7 |
| Week 12 | 5.8 (4.9) | 8.6 (4.4) | −2.8 (−6.3 to 0.7) | −0.5 |
| Wellbeing (WEMWBS) | ||||
| Week 0 | 39.8 (15.4) | 42.3 (13.1) | ||
| Week 2 | 47.4 (10.5) | 44.8 (13.4) | 3.7 (−2.8 to 10.1) | 0.3 |
| Week 4 | 48.3 (11.7) | 45.6 (10.3) | 3.6 (−2.8 to 9.9) | 0.3 |
| Week 12 | 48.3 (12.3) | 44.4 (12.9) | 4.3 (−4.1 to 12.7) | 0.3 |
Data are mean (s.d.).
ISI, Insomnia Severity Index; WEMWBS, Warwick–Edinburgh Mental Wellbeing Scale.
All analyses controlled for stratification factors (insomnia severity, wellbeing and diagnosis).